Fred Hutch Cancer Center

Running trials

• Not yet recruiting

  The PharmFIT Study

  NCT06656936· Source

• Recruiting

  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

  NCT07220187· PHASE3· Source

• Recruiting

  A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  NCT07488923· PHASE1· Source

• Recruiting

  A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

  NCT07564401· PHASE1 PHASE2· Source

• Recruiting

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· PHASE2 PHASE3· Source

• Recruiting

  Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

  NCT06998940· PHASE3· Source

• Recruiting

  A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  NCT06844383· PHASE2· Source

• Not yet recruiting

  The Canopy Cancer Collective Clinical Registry Protocol

  NCT07605702· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· PHASE3· Source

• Recruiting

  Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

  NCT07304154· PHASE1· Source

• Not yet recruiting

  Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

  NCT07224568· PHASE1· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· PHASE1 PHASE2· Source

• Recruiting

  A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06842498· PHASE2· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· PHASE2· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· PHASE1 PHASE2· Source

• Recruiting

  This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

  NCT07121946· PHASE1· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· PHASE2· Source

• Recruiting

  First-in-human Study of 7MW4911 in GI Cancer

  NCT07216560· PHASE1 PHASE2· Source

• Active, not recruiting

  AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

  NCT07285694· PHASE1 PHASE2· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· PHASE2 PHASE3· Source

• Recruiting

  Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  NCT07444814· PHASE1· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· PHASE3· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· PHASE2· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· PHASE3· Source

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· PHASE1 PHASE2· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· PHASE2· Source

• Enrolling by invitation

  A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

  NCT07218003· PHASE1· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· PHASE3· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· PHASE2 PHASE3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· PHASE3· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· PHASE2· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· PHASE2 PHASE3· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· PHASE2 PHASE3· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· PHASE3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· PHASE3· Source

• Recruiting

  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  NCT06859424· PHASE2· Source

• Recruiting

  A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  NCT07066657· PHASE1· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· PHASE3· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· PHASE2 PHASE3· Source

• Recruiting

  A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  NCT07082920· PHASE1· Source

• Not yet recruiting

  EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

  NCT06748872· PHASE1· Source

• Recruiting

  Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  NCT06993844· PHASE1 PHASE2· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· PHASE3· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· PHASE2· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· PHASE3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  NCT06682793· PHASE1 PHASE2· Source

• Active, not recruiting

  Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

  NCT06898957· PHASE1· Source

• Recruiting

  STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  NCT06975293· PHASE1 PHASE2· Source

• Recruiting

  CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  NCT06834282· PHASE1· Source

• Recruiting

  BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  NCT06917079· PHASE1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer23 recruiting
• Colorectal cancer19 recruiting
• Ovarian cancer17 recruiting
• Prostate cancer17 recruiting
• Acute myeloid leukemia14 recruiting
• Pancreatic cancer12 recruiting
• Bladder cancer11 recruiting
• Myelodysplastic syndromes9 recruiting
• Childhood cancers8 recruiting
• Triple-negative breast cancer8 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Diffuse large B-cell lymphoma7 recruiting
• Gastric and esophageal cancer7 recruiting
• Melanoma7 recruiting
• Head and neck cancer6 recruiting
• Metastatic breast cancer6 recruiting
• Multiple myeloma6 recruiting
• Neuroendocrine tumours6 recruiting
• Endometrial cancer5 recruiting
• Kidney cancer5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Cervical cancer4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Mesothelioma4 recruiting
• Sarcoma4 recruiting
• Follicular lymphoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Alzheimer disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· PHASE3· Source

• Recruiting

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· PHASE2· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

  NCT06129422· PHASE1· Source

• Completed

  A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

  NCT05918692· PHASE1· Source

• Completed

  Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

  NCT05592223· PHASE1· Source

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· PHASE2· Source

• Completed

  An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

  NCT05223920· PHASE2· Source

• Completed

  A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

  NCT04699630· PHASE2· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· PHASE2· Source

• Completed

  Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02713386· PHASE1 PHASE2· Source

• Completed

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· PHASE2· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· PHASE3· Source

• Completed

  Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02498600· PHASE2· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· PHASE2 PHASE3· Source

• Completed

  Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

  NCT01771107· PHASE1 PHASE2· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· PHASE2· Source

• Completed

  High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

  NCT00936936· PHASE2· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· PHASE3· Source

Trial sites

• Fred Hutch4 trials
• Fred Hutch Cancer Center11 trials
• Fred Hutchinson Cancer Center231 trials

Conditions

Diseases this institution publishes on or runs trials for.

• HIV424 works · 1 trials
• Prostate cancer412 works · 28 trials
• Lung cancer331 works · 44 trials
• Colorectal cancer316 works · 32 trials
• Multiple myeloma242 works · 14 trials
• Acute myeloid leukemia233 works · 17 trials
• Ovarian cancer120 works · 34 trials
• Acute lymphoblastic leukaemia119 works · 8 trials
• Pancreatic cancer114 works · 26 trials
• Melanoma104 works · 14 trials
• Metastatic breast cancer102 works · 14 trials
• Chronic lymphocytic leukaemia99 works · 10 trials
• Hodgkin lymphoma97 works · 2 trials
• Myelodysplastic syndromes87 works · 12 trials
• Childhood cancers74 works · 20 trials
• Chronic myeloid leukaemia73 works · 6 trials
• Sarcoma63 works · 12 trials
• Follicular lymphoma56 works · 6 trials
• Bladder cancer52 works · 20 trials
• Diffuse large B-cell lymphoma51 works · 12 trials
• Triple-negative breast cancer46 works · 12 trials
• Endometrial cancer41 works · 13 trials
• Head and neck cancer40 works · 11 trials
• Kidney cancer32 works · 8 trials
• Mantle cell lymphoma31 works · 5 trials
• Sickle cell disease20 works · 0 trials
• Myeloproliferative neoplasms8 works · 7 trials